Thirdly, treatment with LDN-212320, an agonist of EAAT2, promoted EAAT2 expression and partially restored motor deficits and neuronal loss in YAPGFAP-CKO ALS mice (Figure 8). Here, SLC1A2 is linked to amyotrophic lateral sclerosis.